Insider transactions

EDGAR

ARCELLX, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
11 transactions, 146,260 shares
Sum of shares × price per share: 14,611,067.2172

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 124

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-04-28 Filed 2026-04-28Behbahani Ali Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)1,925——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Behbahani Ali Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)2,706——0Indirect (I) See Note 2No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
  • F2 The Reporting Person is a trustee of the Ali Behbahani Revocable Trust Dated June 26, 2015 (the Behbahani Trust), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the 1934 Act, as amended, or otherwise of such portion of the securities held by the Behbahani Trust in which the Reporting Person has no pecuniary interest.
Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Behbahani Ali Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94
Disposed (D)11,459——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Behbahani Ali Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30
Disposed (D)8,011——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Behbahani Ali Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68
Disposed (D)9,174——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Ware Olivia C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (36,806) — exercise price 7.61
Disposed (D)36,806——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001663771-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Ware Olivia C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94
Disposed (D)11,459——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001663771-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Ware Olivia C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30
Disposed (D)8,011——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001663771-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Ware Olivia C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68
Disposed (D)9,174——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001663771-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Patel Kavita Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (27,077) — exercise price 6.66
Disposed (D)27,077——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Patel Kavita Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (20,513) — exercise price 15
Disposed (D)20,513——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Patel Kavita Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94
Disposed (D)11,459——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Patel Kavita Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30
Disposed (D)8,011——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Patel Kavita Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68
Disposed (D)9,174——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Galligan Andrew H Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)5,000——0Indirect (I) By trustNo
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
Open filing 0001417976-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Galligan Andrew H Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (16,829) — exercise price 69.87
Disposed (D)16,829——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001417976-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Galligan Andrew H Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,784) — exercise price 63.68
Disposed (D)1,784——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001417976-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Carroll Jill Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)1,479,148——0Indirect (I) See Note 2No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
  • F2 The securities are directly held by SR One Capital Fund I Aggregator, LP (SR One Fund I Aggregator). SR One Capital Partners I, LP (SR One Partners I) serves as the general partner of SR One Fund I Aggregator. The Reporting Person is a partner of SR One Capital Management, LP (SR One Capital Management), an entity affiliated with SR One Fund I Aggregator, and a limited partner of SR One Partners I. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (Section 16), except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
Open filing 0001193125-26-188029 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Carroll Jill Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94
Disposed (D)11,459——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001193125-26-188029 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Carroll Jill Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30
Disposed (D)8,011——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001193125-26-188029 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Carroll Jill Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68
Disposed (D)9,174——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001193125-26-188029 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)67,048——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)5,000——0Indirect (I) By foundationNo
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
  • F2 Shares held by a a family charitable foundation, of which the Reporting Person serves as the President. The Reporting Person has voting and investment power over all securities owned by the foundation.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (40,205) — exercise price 8.66
Disposed (D)40,205——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (32,500) — exercise price 19.97
Disposed (D)32,500——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (70,796) — exercise price 31.03
Disposed (D)70,796——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (94,596) — exercise price 56.15
Disposed (D)94,596——0Direct (D) No
F3
  • F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Unit — underlying Common Stock (20,496)
Disposed (D)20,496——0Direct (D) No
F4, F5
  • F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
  • F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Unit — underlying Common Stock (61,590)
Disposed (D)61,590——0Direct (D) No
F4, F5
  • F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
  • F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Unit — underlying Common Stock (88,542)
Disposed (D)88,542——0Direct (D) No
F4, F5
  • F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
  • F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance-based Restricted Stock Unit — underlying Common Stock (59,028)
Acquired (A)59,028——59,028Direct (D) No
F4, F5
  • F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
  • F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Gilson Michelle Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance-based Restricted Stock Unit — underlying Common Stock (59,028)
Disposed (D)59,028——0Direct (D) No
F4, F5
  • F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
  • F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Lubner David Charles Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)21,659——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Lubner David Charles Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (13,626) — exercise price 6.83
Disposed (D)13,626——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Lubner David Charles Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (59,405) — exercise price 6.28
Disposed (D)59,405——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Lubner David Charles Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (31,794) — exercise price 6.66
Disposed (D)31,794——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Lubner David Charles Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (61,538) — exercise price 15
Disposed (D)61,538——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Lubner David Charles Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94
Disposed (D)11,459——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Lubner David Charles Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30
Disposed (D)8,011——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Lubner David Charles Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68
Disposed (D)9,174——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Myers Kristin Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (16,829) — exercise price 69.87
Disposed (D)16,829——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0002018445-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Myers Kristin Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,784) — exercise price 63.68
Disposed (D)1,784——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0002018445-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Heery Christopher Officer: CHIEF MEDICAL OFFICER
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)23,749——0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Heery Christopher Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (10,901) — exercise price 6.28
Disposed (D)10,901——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Heery Christopher Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (43,604) — exercise price 6.28
Disposed (D)43,604——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Heery Christopher Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (132,416) — exercise price 15
Disposed (D)132,416——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Heery Christopher Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (40,000) — exercise price 19.97
Disposed (D)40,000——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Heery Christopher Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (76,242) — exercise price 31.03
Disposed (D)76,242——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Heery Christopher Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (60,096) — exercise price 56.15
Disposed (D)60,096——0Direct (D) No
F2
  • F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28Heery Christopher Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Unit — underlying Common Stock (13,021)
Disposed (D)13,021——0Direct (D) No
F3, F4
  • F3 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
  • F4 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Paradigm BioCapital Advisors LP Common Stock, $0.001 par value per share0.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097210 Dispute this row
Paradigm BioCapital Advisors GP LLC Common Stock, $0.001 par value per share0.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097210 Dispute this row
Senai Asefaw, M.D. Common Stock, $0.001 par value per share0.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097210 Dispute this row
Paradigm BioCapital International Fund Ltd. Common Stock, $0.001 par value per share0.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097210 Dispute this row
New Enterprise Associates 15, L.P. Common Stock $0.001 par value per share00.0004/28/2026 Filed 2026-04-30SCHEDULE 13D/AAmendment 6Open filing 0001072613-26-000356 Dispute this row
NEA Partners 15, L.P. Common Stock $0.001 par value per share00.0004/28/2026 Filed 2026-04-30SCHEDULE 13D/AAmendment 6Open filing 0001072613-26-000356 Dispute this row
NEA 15 GP, LLC Common Stock $0.001 par value per share00.0004/28/2026 Filed 2026-04-30SCHEDULE 13D/AAmendment 6Open filing 0001072613-26-000356 Dispute this row
Forest Baskett Common Stock $0.001 par value per share00.0004/28/2026 Filed 2026-04-30SCHEDULE 13D/AAmendment 6Open filing 0001072613-26-000356 Dispute this row
Anthony A. Florence, Jr. Common Stock $0.001 par value per share00.0004/28/2026 Filed 2026-04-30SCHEDULE 13D/AAmendment 6Open filing 0001072613-26-000356 Dispute this row
Mohamad H. Makhzoumi Common Stock $0.001 par value per share00.0004/28/2026 Filed 2026-04-30SCHEDULE 13D/AAmendment 6Open filing 0001072613-26-000356 Dispute this row
Scott D. Sandell Common Stock $0.001 par value per share00.0004/28/2026 Filed 2026-04-30SCHEDULE 13D/AAmendment 6Open filing 0001072613-26-000356 Dispute this row
GILEAD SCIENCES, INC. Common Stock, par value $0.001100100.0004/28/2026 Filed 2026-04-28SCHEDULE 13D/AAmendment 1Open filing 0001104659-26-049902 Dispute this row
Rami Elghandour Common stock, par value $0.001 per share0004/28/2026 Filed 2026-04-28SCHEDULE 13D/AAmendment 3Open filing 0001193125-26-187088 Dispute this row
Vestal Point Capital, LP Common Stock, par value $0.001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000902664-26-002548 Dispute this row
Ryan Wilder Common Stock, par value $0.001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000902664-26-002548 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 2Open filing 0000102909-26-000638 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK4.52,653,84802/28/2026 Filed 2026-03-06SCHEDULE 13G/AAmendment 3Open filing 0001897612-26-000310 Dispute this row
FMR LLC COMMON STOCK0.5309,117.4602/27/2026 Filed 2026-03-06SCHEDULE 13G/AAmendment 7Open filing 0000315066-26-000660 Dispute this row
Abigail P. Johnson COMMON STOCK0.5309,117.4602/27/2026 Filed 2026-03-06SCHEDULE 13G/AAmendment 7Open filing 0000315066-26-000660 Dispute this row
Gilead Sciences, Inc. Common Stock, par value $0.00111.56,720,803.0002/23/2026 Filed 2026-02-23SCHEDULE 13DOpen filing 0000904454-26-000123 Dispute this row
New Enterprise Associates 15, L.P. Common Stock $0.001 par value per share5.33,045,262.0002/22/2026 Filed 2026-02-24SCHEDULE 13D/AAmendment 5Open filing 0001072613-26-000212 Dispute this row
NEA Partners 15, L.P. Common Stock $0.001 par value per share5.33,045,262.0002/22/2026 Filed 2026-02-24SCHEDULE 13D/AAmendment 5Open filing 0001072613-26-000212 Dispute this row
NEA 15 GP, LLC Common Stock $0.001 par value per share5.33,045,262.0002/22/2026 Filed 2026-02-24SCHEDULE 13D/AAmendment 5Open filing 0001072613-26-000212 Dispute this row
Forest Baskett Common Stock $0.001 par value per share5.33,045,262.0002/22/2026 Filed 2026-02-24SCHEDULE 13D/AAmendment 5Open filing 0001072613-26-000212 Dispute this row
Anthony A. Florence, Jr. Common Stock $0.001 par value per share5.33,045,262.0002/22/2026 Filed 2026-02-24SCHEDULE 13D/AAmendment 5Open filing 0001072613-26-000212 Dispute this row
Mohamad H. Makhzoumi Common Stock $0.001 par value per share5.33,045,262.0002/22/2026 Filed 2026-02-24SCHEDULE 13D/AAmendment 5Open filing 0001072613-26-000212 Dispute this row
Scott D. Sandell Common Stock $0.001 par value per share5.33,055,360.0002/22/2026 Filed 2026-02-24SCHEDULE 13D/AAmendment 5Open filing 0001072613-26-000212 Dispute this row
Rami Elghandour Common stock, par value $0.001 per share6.43,938,77102/22/2026 Filed 2026-02-24SCHEDULE 13D/AAmendment 2Open filing 0001193125-26-067840 Dispute this row
Vestal Point Capital, LP Common Stock, par value $0.001 per share5.12,925,000.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0000902664-26-001076 Dispute this row
Ryan Wilder Common Stock, par value $0.001 per share5.12,925,000.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0000902664-26-001076 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK18.310,560,42512/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001897612-26-000291 Dispute this row
RA Capital Management, L.P. Common Stock, $0.001 par value per share2.21,267,156.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000033 Dispute this row
Peter Kolchinsky Common Stock, $0.001 par value per share2.21,267,156.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000033 Dispute this row
Rajeev Shah Common Stock, $0.001 par value per share2.21,267,156.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000033 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.001 par value per share2.21,267,156.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000033 Dispute this row
Paradigm BioCapital Advisors LP Common Stock, $0.001 par value per share9.95,724,016.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-016366 Dispute this row
Paradigm BioCapital Advisors GP LLC Common Stock, $0.001 par value per share9.95,724,016.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-016366 Dispute this row
Senai Asefaw, M.D. Common Stock, $0.001 par value per share9.95,724,016.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-016366 Dispute this row
Paradigm BioCapital International Fund Ltd. Common Stock, $0.001 par value per share8.75,055,581.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-016366 Dispute this row
FMR LLC COMMON STOCK6.23,563,728.4612/31/2025 Filed 2026-02-05SCHEDULE 13G/AAmendment 6Open filing 0000315066-26-000369 Dispute this row
Abigail P. Johnson COMMON STOCK6.23,563,728.4612/31/2025 Filed 2026-02-05SCHEDULE 13G/AAmendment 6Open filing 0000315066-26-000369 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK16.69,604,63411/30/2025 Filed 2025-12-05SCHEDULE 13G/AAmendment 1Open filing 0001897612-25-000567 Dispute this row
FMR LLC COMMON STOCK10.45,761,317.4609/30/2025 Filed 2025-11-05SCHEDULE 13G/AAmendment 5Open filing 0000315066-25-002665 Dispute this row
Abigail P. Johnson COMMON STOCK10.45,761,317.4609/30/2025 Filed 2025-11-05SCHEDULE 13G/AAmendment 5Open filing 0000315066-25-002665 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK11.36,275,90708/31/2025 Filed 2025-09-08SCHEDULE 13GOpen filing 0001897612-25-000394 Dispute this row
New Enterprise Associates 15, L.P. Common Stock $0.001 par value per share5.493,045,262.0008/12/2025 Filed 2025-08-14SCHEDULE 13D/AAmendment 4Open filing 0001072613-25-000617 Dispute this row
NEA Partners 15, L.P. Common Stock $0.001 par value per share5.493,045,262.0008/12/2025 Filed 2025-08-14SCHEDULE 13D/AAmendment 4Open filing 0001072613-25-000617 Dispute this row
NEA 15 GP, LLC Common Stock $0.001 par value per share5.493,045,262.0008/12/2025 Filed 2025-08-14SCHEDULE 13D/AAmendment 4Open filing 0001072613-25-000617 Dispute this row
Forest Baskett Common Stock $0.001 par value per share5.493,045,262.0008/12/2025 Filed 2025-08-14SCHEDULE 13D/AAmendment 4Open filing 0001072613-25-000617 Dispute this row
Anthony A. Florence, Jr. Common Stock $0.001 par value per share5.493,045,262.0008/12/2025 Filed 2025-08-14SCHEDULE 13D/AAmendment 4Open filing 0001072613-25-000617 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,686,506 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015103,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,124

Filings made before the SEC required XML are listed, not extracted.

Back to ARCELLX, INC.